Skip to content
Government Federal, Medical Health Aged Care

People living with metastatic breast cancer going to Canberra in call to be counted??

Breast Cancer Network Australia (BCNA) 2 mins read

Not many people know that people living with metastatic breast cancer in Australia are not consistently counted on our cancer registries.  

If you are not counted you are not seen, which means you are ‘invisible’ when health service providers and policymakers plan cancer services and support.  

More than 100 people living with metastatic breast cancer – which is treatable, not curable – took this call to be counted to Canberra. 

Breast Cancer Network Australia (BCNA) – Australia's leading voice for people affected by breast cancer – and Parliamentary Friends of Women's Health are holding a panel discussion – Making Metastatic Breast Cancer Count at Parliament House, Canberra, which will be streamed live.  

Peta Murphy MP, who is living with metastatic breast cancer, and Bridget Archer MP will be co-hosting the panel.  

BCNA Director of Policy, Advocacy and Support Services Vicki Durston and BCNA Consumer Representative Lisa Tobin, from Perth, and who has been living with breast cancer for 23 years and metastatic breast cancer for the past 11 years are also on the panel. 

BCNA kicked off this advocacy campaign in October last year with an issues paper Making Metastatic Breast Cancer Count. 

 

What:             Joint Parliamentary Friends of Women's Health Making Breast Cancer Count

                       Panel discussion: Making Metastatic Breast Cancer Count

                       Hosted by Breast Cancer Network Australia (BCNA)

 

Where:           Main Committee Room 

                      Parliament House 

                       Canberra 

 

When:            8am - 9am Thursday 3 August 2023


About us:

Breast Cancer Network Australia (BCNA) is Australia’s leading breast cancer consumer organisation. BCNA provides information and support to those diagnosed and their supporters, opportunities to connect with others going through a similar situation and work to influence a stronger healthcare system to ensure all Australians affected by breast cancer receive the very best care, treatment and support.


Contact details:

Anna Malbon 

Media & Communications Specialist  

0498 999 477  

amalbon@bcna.org.au  

Media

More from this category

  • Environment, Medical Health Aged Care
  • 01/12/2023
  • 10:43
West Australian doctors peak bodies

WA doctors and health professionals call for the government to take urgent action on climate change and end fossil fuel expansion to protect health

On the 1st December, just prior to the COP28 Health Day on the 3rd December, representatives of the medical colleges for general practitioners (GPs), emergency doctors, rural and remote doctors, and surgeons, as well as other doctors and health professionals, gather at 8 am on the steps of Parliament House to call on the WA Government take urgent action on climate change and protect the health of Western Australians. Reiterating calls from medical colleges earlier this year in support of ending fossil fuel expansion and climate action, those gathered today ask the WA government to: End expansion of any new…

  • Medical Health Aged Care
  • 01/12/2023
  • 10:12
Australian Dental Industry Association

ADIA congratulates Senators of the Inquiry into the Provision of and Access to Dental Services in Australia

1 December The Australian Dental Industry Association congratulates the Senators of the Senate Select Committee Inquiry into the Provision of and Access to Dental…

  • Contains:
  • Medical Health Aged Care, Research Development
  • 01/12/2023
  • 09:17
Aegros

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune

Aegros Releases Top-Line Interim Clinical Trial Results of its COVID-19 Hyperimmune Aegros, an Australian clinical-stage biopharmaceutical company leader in the development and manufacture of plasma derived medicinal products (PDMPs), today announced positive top-line interim results from its CHAT clinical trial. Top-line interim results indicate that Aegros’ COVID-19 hyperimmune provides higher levels of antibodies compared to high-titer convalescent plasma. These results are in line with Aegros’ pre-clinical expectations. CHAT compared Aegros’ COVID-19 hyperimmune to COVID-19 convalescent plasma. The hyperimmune was manufactured using Aegros’ patented Haemafrac® process. A hyperimmune is an intravenous immunoglobulin rich in antibodies that can provide passive immunity for…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.